NCT00391833

Brief Summary

We investigate the clinical efficacy of Panax ginseng in Alzheimer's disease (AD).

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Timeline
Completed

Started Apr 2004

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2004

Completed
1.5 years until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2005

Completed
1.1 years until next milestone

First Submitted

Initial submission to the registry

October 22, 2006

Completed
2 days until next milestone

First Posted

Study publicly available on registry

October 24, 2006

Completed
Last Updated

October 24, 2006

Status Verified

October 1, 2006

First QC Date

October 22, 2006

Last Update Submit

October 22, 2006

Conditions

Alzheimer's DiseaseMemory Decline

Keywords

Alzheimer's disease, Ginseng, CD34

Outcome Measures

Primary Outcomes (2)

  • Cognitive performances monitored by MMSE and Alzheimer's disease assessment scales.

  • Biomarkers including hematopoietic progenitor cell count.

Interventions

Panax GinsengDRUG

Eligibility Criteria

Age40 Years - 83 Years
Sexfemale
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Alzheimer's disease

You may not qualify if:

  • other neurologic disease

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (1)

  • Lee ST, Chu K, Sim JY, Heo JH, Kim M. Panax ginseng enhances cognitive performance in Alzheimer disease. Alzheimer Dis Assoc Disord. 2008 Jul-Sep;22(3):222-6. doi: 10.1097/WAD.0b013e31816c92e6.

    PMID: 18580589DERIVED

MeSH Terms

Conditions

Alzheimer Disease

Interventions

Asian ginseng

Condition Hierarchy (Ancestors)

DementiaBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesTauopathiesNeurodegenerative DiseasesNeurocognitive DisordersMental Disorders

Study Officials

  • Manho Kim, MD, PhD

    Department of Neurology, Seoul National University Hospital

    STUDY CHAIR

Study Design

Study Type
interventional
Phase
phase 1
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER

Study Record Dates

First Submitted

October 22, 2006

First Posted

October 24, 2006

Study Start

April 1, 2004

Study Completion

October 1, 2005

Last Updated

October 24, 2006

Record last verified: 2006-10